Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Palisade Bio, Inc. PALI

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-16.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -16.8
-10M-20M
2009201220152018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2023 · Operating -4356.7%
-50000%-100000%-150000%
200920172025
ROE
FY2025 · ROE -24.5%
-100%-200%
200920172025
Three returns, three denominators.

Each USD of equity lost 25 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -12.2
-10M-20M
200920172025

Total assetsUSD 134.3M
EquityUSD 129.4M
CashUSD 133.4M
Current ratio28.95×

Equity funds 96% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PALI, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.0◌0.00.00.00.00.00.00.00.00.00.00.0◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
Income tax $B0.00.00.00.00.00.0◌◌◌0.00.00.00.00.00.0◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌−0.0−0.0−0.0−0.0−0.0◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.30−10.19−27.01−16.53−169.74−3.72−3.80−7.54−1.20−2.53−2.99−0.26−0.27−0.17−0.26−0.42−0.30
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %−24.5−153.6−103.4−143.7———−67.6−157.9−258.6−184.3−173.2−257.7−234.5−263.2——
Shares out B0.160.000.010.000.000.020.000.020.020.010.090.090.080.070.050.05◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 64 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image